{"id":"W4390588040","doi":"10.1038/s41591-023-02703-y","title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Apheresis Group; Juravinski Cancer Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; McMaster University; London Health Sciences Centre; Dalhousie University","funders":"Genentech; McMaster University; Gilead Sciences; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; London Health Sciences Centre; Amgen; Pfizer; Dalhousie University; Hamilton Health Sciences; GlaxoSmithKline","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Multiple myeloma; Neutropenia; Adverse effect; Dexamethasone; Refractory (planetary science); Oncology; Febrile neutropenia; Gastroenterology; Toxicity","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001894813,0.001328582,0.001308655,0.0003298425,0.0003787511,0.001208113,0.0006017602,0.001257747,0.003840436],"category_scores_gemma":[0.0008738583,0.0004274953,0.001190921,0.0003353015,0.0006732852,0.000800423,0.0003399988,0.002168816,0.0006455191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008605259,"about_ca_system_score_gemma":0.001294446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007727274,"about_ca_topic_score_gemma":0.002117709,"domain_scores_codex":[0.9996023,0.0002071293,0.00001704325,0.00006002519,0.00004316029,0.00007047817],"domain_scores_gemma":[0.9995889,0.00007042086,0.00007452707,0.00002920065,0.00002833702,0.0002086334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8136573,0.04639668,0.002722779,0.001203621,0.001503236,0.0003943537,0.0002978412,0.002174612,0.02198466,0.0006564756,0.008420403,0.1005881],"study_design_scores_gemma":[0.8818458,0.1071404,0.003792851,0.00006535314,0.0002953327,0.0002476938,0.00004110094,0.0009611894,0.001095974,0.0003420477,0.004147958,0.00002445026],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835824,0.006378596,0.0004040496,0.001435266,0.0002617049,0.002941545,0.001424093,0.000111997,0.003460372],"genre_scores_gemma":[0.9766942,0.005684854,0.002097769,0.002707517,0.0004050798,0.003681761,0.002990604,0.00003836512,0.005699745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003840436,"threshold_uncertainty_score":0.0128476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02616673093690118,"score_gpt":0.3845048810255943,"score_spread":0.3583381500886931,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}